1 / 42

sUA Lowering Therapies: The why, the when, the how!

sUA Lowering Therapies: The why, the when, the how!. Presenter:. Speaker Disclosure Statement. Name of presenter/speaker sUA Lowering Therapies: The why, the when, the how ! Financial Disclosure : Grants/Research Support Speaker Bureau/Honoraria Consulting Fees Other .

donal
Télécharger la présentation

sUA Lowering Therapies: The why, the when, the how!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. sUA Lowering Therapies:The why, the when, the how! Presenter:

  2. Speaker Disclosure Statement Name of presenter/speaker sUALowering Therapies:The why, the when, the how! Financial Disclosure: • Grants/Research Support • Speaker Bureau/Honoraria • Consulting Fees • Other

  3. Reduction in Acute Flaresin Years 2 and 3 of Treatment1 100 N = 267 80 Percentage of Patients With Gout Flare Recurrence 60 40 20 0 Mean Serum Urate, µmol/L

  4. .

  5. .

  6. 50 Febuxostat 80 mg Allopurinol 300/200 mg 40 30 Subjects, % 20 10 0 0-4 4-8 8-12 12-16 16-20 20-24 24-28 Time interval (weeks)

More Related